{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:44:10Z","timestamp":1792014250621,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Cedars-Sinai Medical Center","id":[{"id":"https:\/\/ror.org\/02pammg90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40263-026-01334-4","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:57:30Z","timestamp":1790157450000},"page":"1481-1511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9580-6450","authenticated-orcid":false,"given":"Itai","family":"Danovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-6023","authenticated-orcid":false,"given":"Kyla","family":"Truman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haze","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaishav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Totlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Kaidbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleab K.","family":"Tessema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zholi","family":"Minasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-4756","authenticated-orcid":false,"given":"Waguih William","family":"IsHak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-9964","authenticated-orcid":false,"given":"Robert N.","family":"Pechnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"1334_CR1","volume-title":"Global status report on alcohol and health 2018","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). Global status report on alcohol and health 2018. World Health Organization; 2018."},{"issue":"2","key":"1334_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/wps.21073","volume":"22","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Blanco C. Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment, and prevention. World Psychiatry. 2023;22(2):203\u201329. https:\/\/doi.org\/10.1002\/wps.21073.","journal-title":"World Psychiatry"},{"issue":"8","key":"1334_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760\u201373. https:\/\/doi.org\/10.1016\/S2215-0366(16)00104-8.","journal-title":"Lancet Psychiatry"},{"key":"1334_CR4","unstructured":"NIDA. Treatment and recovery. National Institute on Drug Abuse website. https:\/\/nida.nih.gov\/publications\/drugs-brains-behavior-science-addiction\/treatment-recovery. Accessed 15 Feb 2026."},{"key":"1334_CR5","unstructured":"Substance Abuse and Mental Health Services Administration. SAMHSA releases medications for substance use disorders. https:\/\/www.samhsa.gov\/medications-substance-use-disorders. Accessed 15 Feb 2026."},{"issue":"1","key":"1334_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-15","volume":"11","author":"V Smith","year":"2011","unstructured":"Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011;11(1):15. https:\/\/doi.org\/10.1186\/1471-2288-11-15.","journal-title":"BMC Med Res Methodol"},{"key":"1334_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1334_CR8","unstructured":"World Health Organization (WHO). List of WHO-Listed Authorities (WLA) (in alphabetical order) as of December 2025. Located at https:\/\/www.who.int\/initiatives\/who-listed-authority-reg-authorities and https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/regulatory-systems\/wla\/list_of_wla.pdf. Accessed 15 Feb 2026."},{"issue":"5","key":"1334_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.pharma.2025.03.006","volume":"83","author":"V Faillat","year":"2025","unstructured":"Faillat V. The paradigm shift from stringent regulatory authorities to WHO-listed authorities. Ann Pharm Fr. 2025;83(5):810\u20138. https:\/\/doi.org\/10.1016\/j.pharma.2025.03.006.","journal-title":"Ann Pharm Fr"},{"key":"1334_CR10","unstructured":"WHO. International Clinical Trials Registry Platform. Located at https:\/\/trialsearch.who.int. Accessed 15 Feb 2026."},{"key":"1334_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Savovi\u0107 J, Higgins JP, et al. ROBIS: a new tool to assess the risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225\u201334. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.06.005.","journal-title":"J Clin Epidemiol"},{"key":"1334_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"key":"1334_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"1334_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jrsm.1390","volume":"11","author":"EA Hennessy","year":"2020","unstructured":"Hennessy EA, Johnson BT. Examining overlap of included studies in meta-reviews: guidance for using the corrected covered area index. Res Synth Methods. 2020;11(1):134\u201345. https:\/\/doi.org\/10.1002\/jrsm.1390.","journal-title":"Res Synth Methods"},{"issue":"3","key":"1334_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jrsm.1557","volume":"13","author":"J P\u00e9rez-Bracchiglione","year":"2022","unstructured":"P\u00e9rez-Bracchiglione J, Meza N, Bangdiwala SI, Ni\u00f1o de Guzm\u00e1n E, Urr\u00fatia G, Bonfill X, et al. Graphical representation of overlap for overviews: GROOVE tool. Res Synth Methods. 2022;13(3):381\u20138. https:\/\/doi.org\/10.1002\/jrsm.1557.","journal-title":"Res Synth Methods."},{"issue":"17","key":"1334_CR16","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA. 2023;330(17):1653\u201365. https:\/\/doi.org\/10.1001\/jama.2023.19761.","journal-title":"JAMA"},{"issue":"2","key":"1334_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/add.13974","volume":"113","author":"C Palpacuer","year":"2018","unstructured":"Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220\u201337. https:\/\/doi.org\/10.1111\/add.13974.","journal-title":"Addiction"},{"issue":"1","key":"1334_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012557.pub3","volume":"1","author":"R Agabio","year":"2023","unstructured":"Agabio R, Saulle R, R\u00f6sner S, Minozzi S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2023;1(1):CD012557. https:\/\/doi.org\/10.1002\/14651858.CD012557.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1334_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"RK Fuller","year":"1986","unstructured":"Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256(11):1449\u201355. https:\/\/doi.org\/10.1001\/jama.1986.03380110055026.","journal-title":"JAMA"},{"issue":"2","key":"1334_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/add.15572","volume":"117","author":"CE Murphy 4th","year":"2022","unstructured":"Murphy CE 4th, Wang RC, Montoy JC, Whittaker E, Raven M. Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. Addiction. 2022;117(2):271\u201381. https:\/\/doi.org\/10.1111\/add.15572.","journal-title":"Addiction"},{"issue":"5","key":"1334_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/1570159X22666240902100058","volume":"23","author":"L Biso","year":"2025","unstructured":"Biso L, Spini A, Petragnano F, Maggio R, Scarselli M, Carli M. Long-term efficacy and safety of sodium oxybate in treating alcohol use disorder: a systematic review and meta-analysis. Curr Neuropharmacol. 2025;23(5):579\u201393. https:\/\/doi.org\/10.2174\/1570159X22666240902100058.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"1334_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agag005","volume":"61","author":"M Kitamura","year":"2026","unstructured":"Kitamura M, Fukasawa T, Nakagami Y, Shirakawa S, Kawakami K. Initiation of pharmacotherapy for alcohol use disorder in Japan: a longitudinal descriptive study. Alcohol Alcohol. 2026;61(2):agag005. https:\/\/doi.org\/10.1093\/alcalc\/agag005.","journal-title":"Alcohol Alcohol"},{"issue":"7","key":"1334_CR23","doi-asserted-by":"publisher","first-page":"A454","DOI":"10.1016\/j.jval.2014.08.1239","volume":"17","author":"P Kamudoni","year":"2014","unstructured":"Kamudoni P, Gr\u00fcnder G, Sychla H, Juha B. An evaluation of the comparative effectiveness of clomethiazole against diazepam in the treatment of alcohol withdrawal syndrome in routine clinical practice [abstract]. Value Health. 2014;17(7):A454. https:\/\/doi.org\/10.1016\/j.jval.2014.08.1239.","journal-title":"Value Health."},{"issue":"7","key":"1334_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/apt.13965","volume":"45","author":"ET Goh","year":"2017","unstructured":"Goh ET, Morgan MY. Review article: pharmacotherapy for alcohol dependence\u2014the why, the what and the wherefore. Aliment Pharmacol Ther. 2017;45(7):865\u201382. https:\/\/doi.org\/10.1111\/apt.13965.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"1334_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011117.pub3","volume":"9","author":"S Nielsen","year":"2022","unstructured":"Nielsen S, Tse WC, Larance B. Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database Syst Rev. 2022;9(9):CD011117. https:\/\/doi.org\/10.1002\/14651858.CD011117.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1334_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","volume":"10","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Clark B, Macpherson G, et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry. 2023;10(6):386\u2013402. https:\/\/doi.org\/10.1016\/S2215-0366(23)00095-0.","journal-title":"Lancet Psychiatry"},{"key":"1334_CR27","doi-asserted-by":"publisher","DOI":"10.52965\/001c.37517","author":"S Poliwoda","year":"2022","unstructured":"Poliwoda S, Noor N, Jenkins JS, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022 Aug 20;10(3):37517.\u00a0https:\/\/doi.org\/10.52965\/001c.37517.","journal-title":"Health Psychol Res"},{"issue":"2","key":"1334_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/10398562241295872","volume":"33","author":"J McMaster","year":"2025","unstructured":"McMaster J, Abeysundera H. Effectiveness of long-acting buprenorphine\u2014a systematic review. Australas Psychiatry. 2025;33(2):235\u201348. https:\/\/doi.org\/10.1177\/10398562241295872.","journal-title":"Australas Psychiatry"},{"issue":"2","key":"1334_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","volume":"34","author":"M Albayaty","year":"2017","unstructured":"Albayaty M, Linden M, Olsson H, et al. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther. 2017;34(2):560\u201375. https:\/\/doi.org\/10.1007\/s12325-016-0472-9.","journal-title":"Adv Ther"},{"key":"1334_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100133","volume":"6","author":"C Heidbreder","year":"2023","unstructured":"Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep. 2023;6:100133. https:\/\/doi.org\/10.1016\/j.dadr.2023.100133.","journal-title":"Drug Alcohol Depend Rep."},{"issue":"4","key":"1334_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799","volume":"9","author":"J Klimas","year":"2019","unstructured":"Klimas J, Gorfinkel L, Giacomuzzi SM, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9(4):e025799. https:\/\/doi.org\/10.1136\/bmjopen-2018-025799.","journal-title":"BMJ Open"},{"key":"1334_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1003257","volume":"13","author":"M Zangiabadian","year":"2022","unstructured":"Zangiabadian M, Golmohammadi S, Nejadghaderi SA, Zahmatkesh MM, Nasiri MJ, Sadeghian M. The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: a systematic review and meta-analysis. Front Psychiatry. 2022;13:1003257. https:\/\/doi.org\/10.3389\/fpsyt.2022.1003257.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1334_CR33","doi-asserted-by":"publisher","first-page":"e249744","DOI":"10.1001\/jamanetworkopen.2024.9744","volume":"7","author":"M Shulman","year":"2024","unstructured":"Shulman M, Greiner MG, Tafessu HM, et al. Rapid initiation of injection naltrexone for opioid use disorder: a stepped-wedge cluster randomized clinical trial. JAMA Netw Open. 2024;7(5):e249744. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.9744.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1334_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22210-8","volume":"25","author":"LS Fischer","year":"2025","unstructured":"Fischer LS, Asher A, Stein R, et al. Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. BMC Public Health. 2025;25(1):1135. https:\/\/doi.org\/10.1186\/s12889-025-22210-8.","journal-title":"BMC Public Health"},{"issue":"1","key":"1334_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59932-7","volume":"16","author":"MA van Lemmen","year":"2025","unstructured":"van Lemmen MA, van Velzen M, Sarton EY, Dahan A, Niesters M, van der Schrier RM. A comparison of intramuscular (Zimhi) and intranasal naloxone (Narcan) in reversal of fentanyl-induced apnea: a randomized, crossover, open-label trial. Nat Commun. 2025;16(1):4659. https:\/\/doi.org\/10.1038\/s41467-025-59932-7.","journal-title":"Nat Commun"},{"key":"1334_CR36","doi-asserted-by":"publisher","unstructured":"In brief: a new OTC naloxone nasal spray (RiVive).\u00a0Med Lett Drugs Ther. 2024;66(1698):47\u201348. https:\/\/doi.org\/10.58347\/tml.2024.1698d.","DOI":"10.58347\/tml.2024.1698d"},{"issue":"11","key":"1334_CR37","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/add.70060","volume":"120","author":"M Gonzalez Utrilla","year":"2025","unstructured":"Gonzalez Utrilla M, Chesney E, Neale J, Metrebian N, Kalk N, Skulberg AK, et al. Naloxone dosing in the era of synthetic opioids: applying the goldilocks principle. Addiction. 2025;120(11):2165\u201372. https:\/\/doi.org\/10.1111\/add.70060.","journal-title":"Addiction"},{"key":"1334_CR38","doi-asserted-by":"publisher","first-page":"C002024","DOI":"10.1002\/14651858.CD002024.pub5","volume":"5","author":"L Gowing","year":"2016","unstructured":"Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;5:C002024. https:\/\/doi.org\/10.1002\/14651858.CD002024.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1334_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drugalcdep.2005.04.008","volume":"80","author":"MG Klous","year":"2005","unstructured":"Klous MG, Van den Brink W, Van Ree JM, Beijnen JH. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend. 2005;80(3):283\u201395. https:\/\/doi.org\/10.1016\/j.drugalcdep.2005.04.008.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"1334_CR40","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/jcph.70088","volume":"65","author":"A Cipriano","year":"2025","unstructured":"Cipriano A, He E, Shet M, Apseloff G, Harris SC. Reversal of fentanyl-induced respiratory depression in healthy subjects by intramuscular nalmefene administered by auto-injector versus intranasal naloxone. J Clin Pharmacol. 2025;65(12):1661\u201375. https:\/\/doi.org\/10.1002\/jcph.70088.","journal-title":"J Clin Pharmacol"},{"key":"1334_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-7517-4-5","volume":"4","author":"II Michels","year":"2007","unstructured":"Michels II, St\u00f6ver H, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduct J. 2007;4:5. https:\/\/doi.org\/10.1186\/1477-7517-4-5.","journal-title":"Harm Reduct J"},{"issue":"9","key":"1334_CR42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","volume":"69","author":"E Krupitsky","year":"2012","unstructured":"Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973\u201381. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2012.1a.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1334_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bcpt.12434","volume":"118","author":"EI Penninga","year":"2016","unstructured":"Penninga EI, Graudal N, Ladekarl MB, J\u00fcrgens G. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication\u2014a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol. 2016;118(1):37\u201344. https:\/\/doi.org\/10.1111\/bcpt.12434.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1334_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000031.pub5","volume":"4","author":"S Howes","year":"2020","unstructured":"Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020;4:CD000031. https:\/\/doi.org\/10.1002\/14651858.CD000031.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1334_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub8","volume":"5","author":"J Livingstone-Banks","year":"2023","unstructured":"Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023;5(5):CD006103. https:\/\/doi.org\/10.1002\/14651858.CD006103.pub8.","journal-title":"Cochrane Database Syst Rev"},{"key":"1334_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub5","volume":"5","author":"J Hartmann-Boyce","year":"2018","unstructured":"Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146. https:\/\/doi.org\/10.1002\/14651858.CD000146.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"1334_CR47","unstructured":"ClinicalTrials.gov. Dutasteride treatment for reducing heavy drinking in aud: predictors of efficacy. https:\/\/clinicaltrials.gov\/study\/NCT04098302. Accessed 1 Apr 2026."},{"key":"1334_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001609","author":"J Covault","year":"2025","unstructured":"Covault J, Tennen H, Feinn R. Dutasteride as a treatment to support reduced drinking: a randomized placebo-controlled trial. J Addict Med. 2025. https:\/\/doi.org\/10.1097\/ADM.0000000000001609.","journal-title":"J Addict Med"},{"key":"1334_CR49","unstructured":"ClinicalTrials.gov. Study to evaluate AD04 in adults with alcohol use disorder (AUD) and selected serotonin transporter polymorphisms (ONWARD). https:\/\/clinicaltrials.gov\/study\/NCT04101227. Accessed 1 Apr 2026."},{"key":"1334_CR50","doi-asserted-by":"publisher","unstructured":"Johnson B, Alho H, Addolorato G, Lesch OM, Chick J, Liu L, et al. Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes. Eur J Intern Med. 2024 Sep;127:50-62. https:\/\/doi.org\/10.1016\/j.ejim.2024.06.001.","DOI":"10.1016\/j.ejim.2024.06.001"},{"key":"1334_CR51","unstructured":"ClinicalTrials.gov. Zonisamide treatment of alcohol use disorder: an evaluation of efficacy and mechanism of action. https:\/\/clinicaltrials.gov\/study\/NCT02900352. Accessed 1 Apr 2026."},{"key":"1334_CR52","unstructured":"ClinicalTrials.gov. Accelerated development of additive pharmacotherapy treatment (adapt-2) for methamphetamine use disorder (ADAPT-2). https:\/\/clinicaltrials.gov\/study\/NCT03078075. Accessed 1 Apr 2026."},{"issue":"10","key":"1334_CR53","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/add.16529","volume":"119","author":"MJ Li","year":"2024","unstructured":"Li MJ, Chau B, Belin T, Carmody T, Jha MK, Marino EN, et al. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Addiction. 2024;119(10):1840\u20135. https:\/\/doi.org\/10.1111\/add.16529.","journal-title":"Addiction"},{"issue":"2","key":"1334_CR54","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2020214.","journal-title":"N Engl J Med"},{"issue":"4","key":"1334_CR55","doi-asserted-by":"publisher","DOI":"10.31083\/JIN26361","volume":"24","author":"K Draghmeh","year":"2025","unstructured":"Draghmeh K, Fuehrlein B. Emerging therapeutics in the treatment of substance use disorders: a focus on GLP-1 receptor agonists, D3R antagonists, and CRF antagonists. J Integr Neurosci. 2025;24(4):26361. https:\/\/doi.org\/10.31083\/JIN26361.","journal-title":"J Integr Neurosci"},{"issue":"10","key":"1334_CR56","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022;79(10):953\u201362. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096.","journal-title":"JAMA Psychiat"},{"issue":"11","key":"1334_CR57","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1176\/appi.ajp.20231023","volume":"181","author":"CG Imperio","year":"2024","unstructured":"Imperio CG, Levin FR, Martinez D. The neurocircuitry of substance use disorder, treatment, and change: a resource for clinical psychiatrists. Am J Psychiatry. 2024;181(11):958\u201372. https:\/\/doi.org\/10.1176\/appi.ajp.20231023.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1334_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/medicines13010007","volume":"13","author":"M Cheibub David Marin","year":"2026","unstructured":"Cheibub David Marin M, Pozzolo Pedro MO, Perrotte G, Castaldelli-Maia JM. Pharmacotherapy for alcohol craving reduction: efficacy of short-term treatments in alcohol use disorder. Medicines (Basel). 2026;13(1):7. https:\/\/doi.org\/10.3390\/medicines13010007.","journal-title":"Medicines (Basel)."},{"key":"1334_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0159","author":"R McKetin","year":"2026","unstructured":"McKetin R, Shoptaw S, Saunders L, et al. Mirtazapine for methamphetamine use disorder: a randomized clinical trial. JAMA Psychiat. 2026;83(6):581.https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0159.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1334_CR60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40263-022-00918-0","volume":"36","author":"A Hamidovic","year":"2022","unstructured":"Hamidovic A. Dual orexin receptor antagonists (DORAs) as an adjunct treatment for smoking cessation. CNS Drugs. 2022;36(5):411\u20137. https:\/\/doi.org\/10.1007\/s40263-022-00918-0.","journal-title":"CNS Drugs"},{"key":"1334_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106311","volume":"176","author":"CGJ Guerrin","year":"2025","unstructured":"Guerrin CGJ, Tesselaar DRM, Booij J, Schellekens AFA, Homberg JR. Precision medicine in substance use disorders: integrating behavioral, environmental, and biological insights. Neurosci Biobehav Rev. 2025;176:106311. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106311.","journal-title":"Neurosci Biobehav Rev"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01334-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:44:20Z","timestamp":1792010660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01334-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01334-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no potential competing interests with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are available upon request from the corresponding author.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Itai Danovitch, Robert N. Pechnick, Waguih William IsHak, Kyla Truman, and Daniel N. Kaidbay contributed to the conceptualization and methodology of the article. The literature search and formal analysis were performed by Kyla Truman, Haze Brown, Macie Miller, Shaishav Shah, Jayant Totlani, Daniel N. Kaidbay, Kaleab K. Tessema, Zholi Minasyan, and Samuel Miles. The first draft of the manuscript was written by Itai Danovitch, Kyla Truman, Daniel N. Kaidbay, and Robert N. Pechnick. All authors critically edited and revised the work. All authors read and approved the final manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}